Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

In men with metastatic, hormone-sensitive prostate cancer who were receiving testosterone suppression, the addition of enzalutamide led to significantly longer progression-free and overall survival than the addition of standard nonsteroidal antiandrogen therapy. The better outcome was less clear amo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-07, Vol.381 (2), p.121-131
Hauptverfasser:	Davis, Ian D, Martin, Andrew J, Stockler, Martin R, Begbie, Stephen, Chi, Kim N, Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E, Horvath, Lisa G, Joshua, Anthony M, Lawrence, Nicola J, Marx, Gavin, McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A, Parnis, Francis, Parulekar, Wendy, Pook, David W, Reaume, M. Neil, Sandhu, Shahneen K, Tan, Alvin, Tan, T. Hsiang, Thomson, Alastair, Tu, Emily, Vera-Badillo, Francisco, Williams, Scott G, Yip, Sonia, Zhang, Alison Y, Zielinski, Robert R, Sweeney, Christopher J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - secondary Aged Androgen Receptor Antagonists - adverse effects Androgen Receptor Antagonists - therapeutic use Androgen receptors Androgens Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone Neoplasms - drug therapy Bone Neoplasms - secondary Cancer therapies Castration Clinical trials Design Digestive System Neoplasms - drug therapy Digestive System Neoplasms - secondary Fatigue - chemically induced Follow-Up Studies Humans Kaplan-Meier Estimate Male Medical imaging Medical research Metastases Metastasis Middle Aged Patients Phenylthiohydantoin - adverse effects Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - therapeutic use Progression-Free Survival Prostate cancer Prostate-specific antigen Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Seizures Seizures - chemically induced Survival Testosterone
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In men with metastatic, hormone-sensitive prostate cancer who were receiving testosterone suppression, the addition of enzalutamide led to significantly longer progression-free and overall survival than the addition of standard nonsteroidal antiandrogen therapy. The better outcome was less clear among patients who had received docetaxel.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1903835